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Abstract: Chronic cancer and nonmalignant pain (CNMP) is a common and major health 
problem afﬂ  icting approximately 40 million persons in the US. Most cancer patients, and many 
patients with CNMP, require opioid analgesics to obtain adequate pain relief. Oral oxymorphone 
is a new formulation of an existing parenteral opioid that has become available for the treatment 
of signiﬁ  cant pain: acute postoperative, chronic arthritis, chronic low back, and chronic cancer 
pain. Oxymorphone is a typical mu-opioid agonist that is effective in both immediate- and 
extended-release (IR and ER) formulations. Oxymorphone is more lipid soluble than morphine, 
resulting in a rapid onset of action when given in tablet formulation, with a duration of action 
of approximately 4–6 hours in IR and 12 hours in ER preparations. Oxymorphone provides 
excellent pain relief for signiﬁ  cant pain, with typical opioid side effects that are usually mild 
or moderate in intensity. Multiple double-blind, prospective, placebo-controlled clinical trials 
have demonstrated the clinical efﬁ  cacy and safety of this new oral opioid preparation. Oral 
oxymorphone is an effective opioid that provides a new therapeutic option for the physician.
Keywords: chronic pain, oxymorphone, opioids, extended-release, sustained-release, 
cancer pain
Introduction
Chronic pain, including cancer pain and chronic nonmalignant pain (CNMP), is a 
common and major health problem afﬂ  icting a signiﬁ  cant number of patients, result-
ing in personal suffering, reduced productivity, and substantial health care costs. 
Musculoskeletal conditions such as low back pain, osteoarthritis, and myofascial pain 
are the leading causes of disability in individuals of working age (Yelin and Callahan 
1995), and recently the Centers for Disease Control and Prevention issued estimates of 
the number of adults with arthritis and chronic joint symptoms at 70 million persons 
(CDC 2002). Total disability expenditures among US working adults cost the country 
over US$200 billion per year and social security insurance beneﬁ  ts are far outstripping 
the increase in the working population insured for disability (Sloan and Babul 2006). 
Untreated chronic pain has been documented to interfere with sleep patterns, increase 
anxiety and depression, decrease quality of life, interfere with social relationships, 
and decrease the ability of a patient to cope with life (McCarberg 2007). Clearly, the 
treatment of patients suffering from CNMP is required from a humanitarian viewpoint 
in addition to the practice of good medicine.
Treatment for CNMP is frequently, and appropriately, initiated with nonopioid 
analgesics such as acetaminophen, and nonsteroidal anti-inflammatory drugs 
(NSAIDs). Not only do all of these agents have their own set of adverse reactions 
(such as gastric ulcers, renal and liver toxicity, and bleeding) but many patients fail 
to obtain effective pain relief with analgesics that have a ceiling effect. Only in recent 
years have opioid analgesics been recommended and evaluated in controlled clinical 
trials for the relief of CNMP (Portenoy 1996; Markenson et al 2005). While opioids Therapeutics and Clinical Risk Management 2008:4(4) 778
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have been known to provide excellent analgesia since ancient 
times, a concern of both clinicians and the general public 
with the use of chronic opioids to treat CNMP was the risk of 
addiction. A current consensus viewpoint is that most patients 
with CNMP can obtain chronic pain relief with opioids at low 
opioid addiction risk (Gagnon et al 2007), particularly when 
addiction risk assessment tools are used during initiation of 
opioid therapy (Kalso et al 2004; Belgrade et al 2006). The 
careful use of chronic opioids in the treatment of CNMP is 
thus becoming more prevalent. Chronic opioids, traditionally 
used in adults alone, have recently been recommended in 
children with chronic pain from rheumatic arthritis refractory 
to standard analgesic therapies (Kimura and Walco 2007). 
This review paper will focus on oral oxymorphone extended-
release (ER) in the management of CNMP.
Chronic pain is common among cancer patients in the 
end stages of life, is one of the most feared consequences of 
cancer, and is a major contributor to the morbidity associated 
with cancer (Sloan and Melzack 1999). It is well established 
that orally administered, chronic opioids titrated to pain relief 
among cancer patients with pain will provide effective anal-
gesia for the majority of patients (Melzack et al 1976). While 
early clinical trials demonstrated the efﬁ  cacy of immediate-
release (IR) oral opioids in the treatment of cancer pain, the 
introduction of oral ER opioids has been viewed as a major 
advance in the management of chronic cancer pain (Thirwell 
et al 1989). Oral opioids are noninvasive, convenient, easy 
to titrate, inexpensive, and because cancer pain requires 
around-the-clock treatment, ER formulations providing 
12- or 24-hour dosing are preferable (Dhaliwal et al 1995). 
This review paper will focus on oral oxymorphone ER in the 
management of cancer pain.
Opioids have been used in the effective treatment of post-
operative pain since the invention of the hypodermic syringe 
and hollow needle in the 1850s (Brownstein 1993). Acute 
postsurgical pain is both common and frequently under-
treated (Apfelbaum et al 2003), and becoming increasingly 
associated with same-day outpatient surgery. With varying 
and unpredictable levels of patient pain there is a need for 
ﬂ  exible analgesic modalities that can be adjusted quickly to 
the level of pain rating (Gimbel et al 2005). Oxymorphone 
IR may be particularly useful for the treatment of postsur-
gical pain and is a focus of this review paper. Although 
nonopioid methods of postoperative analgesia exist (eg, local 
anesthetic nerve blocks, local anesthetic wound inﬁ  ltration 
systems, NSAIDs), standard intermittent oral opioid analge-
sics continue to be the mainstay for postoperative pain relief. 
It is likely that multimodal therapy using a combination of 
opioids, NSAIDs and other nerve blocks will achieve the 
best pain relief after surgery.
Oral oxymorphone has recently become available for the 
treatment of acute and chronic signiﬁ  cant pain. Morphine 
and other opioids have been prescribed for many years in the 
treatment of cancer pain, and in the past decade for the treat-
ment of CNMP, and have been found to be effective for the 
relief of moderate to severe pain (Sloan 2007). Why should 
a new oral opioid formulation, oxymorphone, be of interest 
to the current clinician? The answer lies in the observed 
variability in patient response to opioids in both analgesia 
and adverse events. Opioids are known to activate opioid 
receptors in the central nervous system (CNS); however, 
a given patient may or may not obtain adequate analgesia 
without intolerable side effects from a given opioid. There 
is, in other words, tremendous variability in an individual 
patient’s analgesic response to a given opioid (Swegle and 
Logemann 2006). The reasons for this variable response to 
opioid analgesia include differences in drug potency, dif-
ferences in drug metabolism, the rate of release of IR and 
ER formulations, differences in opioid receptor-binding 
afﬁ  nity, concurrent medications, production of active opioid 
metabolites, and differences in balance of analgesic versus 
hyperalgesic action of opioids (Sloan et al 2005). Thus, in 
order to improve opioid analgesia in patients with chronic 
pain, clinicians will often rotate to a different opioid. In fact, 
20% of cancer patients rotate through three or more opioids 
before achieving an acceptable balance between analgesia 
and side effects (Cherny et al 1995). Therefore, expanding 
the number of oral opioids available to our patients should 
help in terms of treatment options and dose ﬂ  exibility. In 
addition, oxymorphone may hold speciﬁ  c chemical and phar-
macokinetic properties (see below) that may be particularly 
favorable for use in chronic pain management.
Chemistry
Opioids have been used as analgesics since ancient times and 
were found in the early 1970s to act upon opioid receptors 
in the central nervous system. Opioids are known to activate 
stereospeciﬁ  c G-protein opioid receptors on cell membranes 
but the exact mechanism of action is still not fully under-
stood. In general, opioids act upon mu-, delta-, and kappa-
receptors on CNS neurons producing analgesia via decreased 
neuronal neurotransmitter release and decreased nocicep-
tive impulse propagation (Kalso et al 2004). Opioids also 
may have seemingly paradoxical effects producing hyper-
algesia (Wilder-Smith and Arendt-Nielsen 2006), although 
this is a less frequent, and likely dose-related, response.Therapeutics and Clinical Risk Management 2008:4(4) 779
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The mechanisms behind this paradoxical opioid effect 
are beyond the scope of this article but may pertain to 
dose-related opioid excitatory effects at the opioid recep-
tor (Sloan and Hamann 2006), or may result from opioid 
stimulation of CNS glial cells which then release cytokines 
that “oppose” the analgesic effect of the opioid (Watkins 
et al 2007).
Oxymorphone is a mu-opioid agonist analgesic that has 
been available in parenteral formulation since 1959. Indeed, 
some of the earliest studies of parenteral opioids for the treat-
ment of cancer pain and postoperative pain were completed 
using oxymorphone (Beaver and Feise 1977; Beaver et al 
1977). Oxymorphone hydrochloride is a semisynthetic opioid 
agonist that modulates pain and provides signiﬁ  cant analgesia 
because of speciﬁ  city at the mu-opioid receptor (Metzger et al 
2001). Its systematic name is 14-hydroxydihydromorphinone 
and it is synthesized (Figure 1) from thebaine or morphine, 
producing an odorless white crystal or powder, with the 
chemical formula C17H19NO4. Esteriﬁ  cation of the hydroxyl 
groups will in fact produce a more potent opioid but none is 
currently available commercially.
Compared with other opioids, oxymorphone is more 
lipid soluble than morphine or oxycodone (Poyhia and 
Seppala 1994) which results in a more rapid transfer across 
the blood – brain barrier (Metzger et al 2001). Because of 
this rapid entry into the brain, the time to maximum plasma 
concentration (Tmax) of oxymorphone IR in humans is shorter 
(0.5 h) compared with morphine IR (1.2 hours) or oxycodone 
IR (1.5 hours) (Adams and Ahdieh 2005). It is possible that 
the shorter Tmax will result in more rapid onset of analgesia 
compared with other opioids.
Oxymorphone is available for parenteral injection 
(Numorphan®: 1 and 1.5 mg/mL), suppository (Numorphan®: 
5 mg), oral IR tablets (Opana®: 5 and 10 mg), and oral ER 
tablets (Opana® ER: 5, 10, 20, and 40 mg).
Pharmacokinetics
This review will only consider the pharmacology and efﬁ  cacy 
of the newly released oral IR and ER tablet formulations of 
oxymorphone.
Oxymorphone IR tablets
Oxymorphone is well absorbed from the gut but the liver 
eliminates most of the drug during the ﬁ  rst-pass; thus the oral 
bioavailability of oxymorphone is 10% (Sloan et al 2005). 
The astute reader will not interpret this as incompatible with 
good clinical efﬁ  cacy, as oral morphine also has a low oral 
bioavailability of 15%–30% and is clearly effective in the 
management of chronic cancer pain (Thirwell et al 1989). 
The absorbed lipid-soluble oxymorphone easily and rapidly 
enters the CNS, binding to mu-opioid receptors to produce 
analgesia. Oxycodone, by contrast, exhibits a substantial 
analgesic effect from binding to kappa-opioid receptors in 
the spinal cord (Ross and Smith 1997) which may explain, 
in part, the individual variable analgesic and side effect 
response to a given opioid. The volume of distribution of 
oxymorphone is 3 L/kg (similar to morphine) with protein 
binding of about 10%.
Figure 1 Oxymorphone: structure similar to morphine and thebaine.
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Plasma concentrations reach Tmax at 0.5 hours after single 
doses (5, 10, or 20 mg) in healthy volunteers (Adams and 
Ahdieh 2005). This correlates well with a recent clinical trial 
of oxymorphone IR 5 mg tablets for the treatment of acute 
postsurgical pain where onset and time to peak analgesia 
was seen at 0.5 and 1.0 hours, respectively (Gimbel et al 
2005). In a volunteer study, maximum plasma concentra-
tions (Cmax) and area under the plasma concentration versus 
time curve (AUC) increased proportional to the single dose 
range of 5–20 mg, conﬁ  rming linear pharmacokinetics. 
These simple, but important, data imply that an increase in 
dose in the clinical setting will produce predictable increases 
in oxymorphone plasma levels (Adams and Ahdieh 2005). 
After a 1-week dosing of oxymorphone every 6 hours, similar 
linear results (Figure 2) were observed for Cmax and AUC 
at steady state. Plasma oxymorphone concentrations taken 
during the multiple-dose period showed that Tmax remained at 
0.5 hours and that steady-state was achieved after 3 days of 
oxymorphone IR dosing (Adams and Ahdieh 2005). Inges-
tion of food along with oxymorphone increases the Cmax by 
38%–50% (The Medical Letter 2007); thus it may be advis-
able to take the drug on an empty stomach.
Oxymorphone is highly metabolized in the liver 
(principally conjugation with glucuronide) with only 2% 
excreted unchanged by the kidney (Adams and Ahdieh 
2005). The main metabolite is oxymorphone-3-glucuronide, 
with a lesser amount of 6-OH-oxymorphone formed. 
The analgesic activity of oxymorphone-3-glucuronide is 
unknown. At steady-state conditions, 6-OH-oxymorphone 
plasma concentrations approximate those of oxymorphone, 
and the glucuronide metabolite is 90-fold higher than 
oxymorphone (Endo Pharmaceuticals 2007). During dose 
escalation, the oxymorphone metabolites also increase 
in a proportional manner. With healthy volunteer studies 
(Adams and Ahdieh 2005) the elimination half-life was 
approximately 8 hours, about double that of both morphine 
and oxycodone.
Oxymorphone ER tablets
Oxymorphone ER is a new tablet formulation of oxymor-
phone that utilizes the proprietary TIMERx® technology 
(Penwest Pharmaceuticals) which allows 12-hour dosing 
of medication (Oxymorphone-Endo/Penwest 2003). This 
controlled-release technology inserts the opioid into an 
agglomerated hydrophilic matrix which releases the drug (as 
water penetrates the matrix) to sustain plasma levels during 
the 12-hour dosing interval.
As with oxymorphone IR, volunteer studies on healthy 
persons (Adams and Ahdieh 2004) have characterized 
the basic pharmacokinetics of oxymorphone ER. Single-
dose pharmacokinetics demonstrate dose-proportionality 
and linearity over the dose range of 5–40 mg. Oxymor-
phone metabolites also increase in a linear fashion after 
single- and multiple-dose administration. The elimination 
half-life from single-dosing of oxymorphone ER was 
approximately 10 hours, quite similar to the half-life of 
oxymorphone IR. Figure 3 demonstrates the plasma levels 
of oxymorphone sustained over the 12-hour dosing interval 
and with very little ﬂ  uctuation in plasma concentration 
over the dosing interval. Steady-state conditions were 
achieved after 3 days of 12-hour dosing. Tmax occurred at 
just 1.5–3.5 hours; however a careful inspection of Figure 3 
reveals that Tmax was sustained until approximately 6 hours, 
Figure 2 Mean single-dose and steady-state (q6 h dosing) plasma concentrations 
of oxymorphone IR (5, 10, and 20 mg doses) in healthy volunteers. Reprinted with 
permission from Adams MP,  Ahdieh H. 2005. Single- and multiple-dose pharmacokinetic 
and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D, 
6:91–9. Copyright © 2005 Lippincott Williams and Wilkins.
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at which time the plasma concentration started to fall to 
trough levels. These pharmacokinetic data correlate quite 
well with the single published clinical study of oxymor-
phone ER for the treatment of postsurgical pain, in which 
analgesia was noted to occur approximately 2 hours after 
oxymorphone administration, and lasted at least 12 hours 
(Ahdieh et al 2004).
Oxymorphone from the ER preparation is obviously 
metabolized by the liver in the same fashion as for the 
IR compound. As doses increase, plasma levels of oxy-
morphone metabolites (6-hydroxymorphone and oxymor-
phone-3-glucuronide) increase in a linear fashion after 
both single- and multiple-dose administration (Ahdieh 
et al 2004).
In vitro studies show no effect of alcohol on the release 
of oxymorphone ER from the matrix; however, a volunteer 
study (Endo Pharmaceuticals 2007) showed that following 
the concomitant administration of 240 mL of 20% ethanol, 
the Cmax increased on average by 31%, with a wide range of 
variation. Thus, as with all opioids, consumption of alcohol 
beverages should be avoided. A volunteer study in healthy 
individuals showed that when oxymorphone was taken with 
a high-fat meal, the Cmax was increased by 38% compared 
with fasted volunteers (Endo Pharmaceuticals 2007). It is 
recommended to take oxymorphone on an empty stomach. As 
with many medications, plasma levels of oxymorphone were 
found to be higher (40%) in elderly than younger subjects. 
There is no known gender effect on the pharmacokinetics 
of oxymorphone.
Clinical application
Oxymorphone IR tablets
Oxymorphone IR is recommended for the treatment of 
moderate to severe pain, typically for the management of 
postsurgical pain when nonopioid analgesics are not expected 
to provide adequate analgesia. Opioid IR medications are also 
used as PRN rescue analgesics for patients on long-acting 
opioids for the management of cancer or CNMP. Tradition-
ally, short-acting opioids have been used in initial trials for 
patients with CNMP to determine the correct daily dose of 
opioid, followed by conversion to the corresponding ER 
formulation of the same opioid for long-term use (Sinatra 
2006). Some clinicians continue to utilize IR opioids long 
term for the treatment of CNMP as the incidence of opioid 
side effects is often similar between IR and ER opioid prepa-
rations (Hale et al 1999).
Two recent clinical trials have assessed the efﬁ  cacy and 
safety of oral oxymorphone IR for the treatment of post-
operative pain. Gimbel and Ahdieh reported results from 
a multicenter, double-blind, randomized, prospective and 
placebo-controlled clinical trial in 258 patients receiving 
total hip or total knee replacement surgery (Gimbel and 
Ahdieh 2004). Patients were randomized to receive in the 
postoperative period a single dose of oxymorphone IR (10, 
Figure 3 Mean steady-state plasma concentrations of oxymorphone ER over the 12-hour dosing interval in healthy volunteers. Reprinted with permission from Adams MP, 
Ahdieh H. 2004. Pharmacokinetics and dose-proportionality of oxymorphone ER and its metabolites: results of a randomized crossover study. Pharmacotherapy, 24:468–76. 
Copyright © 2004 Pharmacotherapy Publications.
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20, or 30 mg), oxycodone 10 mg, or placebo within 6 hours 
of discontinuing parenteral opioids and when pain intensity 
was rated at 45 mm on a 0–100 mm pain visual analog 
scale (VAS). Patients were monitored for efﬁ  cacy and side 
effects during an 8-hour period. Patients (n = 164) who 
completed this single-dose phase entered a multiple-dose 
period and received either oxymorphone IR or oxycodone IR 
every 4–6 hours PRN for an additional 48 hours. All doses 
of oxymorphone IR provided greater postsurgical analgesia 
compared with placebo (p  0.05). The median time to 
“meaningful” pain relief for patients receiving oxymorphone 
IR was 1 hour. All oxymorphone IR groups maintained 
analgesia during the 48-hour multi-dose phase with median 
PRN dosing intervals of 7–9 hours. Of note, an analgesic 
plateau seemed to appear with the 20 mg dose providing 
analgesia equal to the 30 mg dose. Opioid-related side 
effects were typical (nausea, vomiting, somnolence), rated 
as mild – moderate, and similar between the two opioids. 
The same research group studied the efﬁ  cacy and safety of 
a lower dose (5 mg) of oxymorphone IR for the treatment 
of mild to moderate pain after outpatient knee arthroscopy 
(Gimbel et al 2005). This prospective, randomized, double-
blind, placebo-controlled trial studied 122 patients who 
took study medication on a PRN basis (maximum dose 
medication q1 h) and were followed for 8 hours postdose. 
Oxymorphone 5 mg IR was effectively titrated by patients 
to relieve mild to moderate postoperative pain (pain VAS 
of approximately 35/100 over 8 hours) compared with the 
placebo group (p  0.05) and the mean dosing interval 
was 1.9 hours. Side effects were common (approximately 
50%), mild (nausea, headache), and equal compared with 
the placebo group.
Oxymorphone IR was used open-label to determine daily 
dosing required in a study of oxymorphone ER; however, data 
on the oxymorphone IR phase were not published (Gabrail 
et al 2004). Two studies on the efﬁ  cacy of oxymorphone 
ER for chronic pain (Sloan et al 2005; Katz et al 2007) have 
used oxymorphone IR as PRN rescue analgesics but have not 
published data speciﬁ  cally on the IR preparation.
Oxymorphone ER tablets
Oxymorphone ER has been studied most extensively as a 
12-hour medication in the long-term treatment of chronic 
pain, with 2 published studies for cancer pain and 6 published 
studies for CNMP, for a total of 887 patients completing the 
various clinical trials. Other competing oral ER opioids in the 
US include morphine, oxycodone, and tramadol. Methadone, 
a long-acting oral opioid with a half-life of 1 day, is also used 
in the treatment of chronic pain, as is a long-acting transder-
mal preparation of fentanyl. Additional oral ER opioids under 
investigation or available in other countries include codeine, 
hydromorphone, hydrocodone, and dihydrocodeine. ER oral 
opioids were developed in the 1980s to improve quality of 
life for our patients by offering: improved convenience, 
improved compliance, improved pain control, reduced 
opioid side effects, reduced pill burden, reduced night time 
pain, and improved sleep (Sloan and Babul 2006). Clinical 
trials comparing comparable ER with IR opioids, however, 
often show little difference with quality of pain relief or 
frequency of side effects (Hays et al 1994; Stambaugh et al 
2001). Nonetheless, ER products have reduced pill burden, 
improved convenience, and patients often prefer the ER 
formulation over an IR formulation in the setting of chronic 
pain treatment (Broomhead et al 1997).
Two clinical trials have been published demonstrating 
the effectiveness of oxymorphone ER for the treatment 
of chronic cancer pain. Sloan and colleagues assessed the 
efﬁ  cacy and safety of oxymorphone ER compared to mor-
phine ER or oxycodone ER, among 86 patients with cancer 
pain (Sloan et al 2005). Patients were titrated (open-label, 
prospective) and treated for 7 days on either morphine ER 
or oxycodone ER, and then crossed over for an additional 
7 days of treatment at an estimated equianalgesic dose of 
oxymorphone ER. There were no signiﬁ  cant differences in 
daily pain scores (Figure 4) between oxymorphone ER and 
the alternative opioids, indicating similar analgesia among 
groups. When compared with morphine ER, patients on 
oxymorphone ER used less rescue analgesics, suggesting 
that oxymorphone ER may have a longer duration of activ-
ity than morphine ER. At study conclusion, equianalgesic 
dose ratios of morphine ER and oxycodone ER (Figure 5) 
were calculated to be 1.8:1 and 1.2:1, respectively. The side 
effects were mild, typical for opioids (nausea, drowsiness), 
and similar for all opioids. Gabrail and colleagues (Gabrail 
et al 2004) reported results of a double-blind, crossover 
study of oxymorphone ER for the treatment of cancer pain. 
Forty patients completed the entire study which used IR 
oxymorphone or oxycodone to achieve adequate pain relief 
among patients, and then convert patients to the ER formu-
lation for another 7–10 days. Patients were then crossed 
over (double-blind fashion) to the alternative medication 
for an additional 7–10-day period. Both oxymorphone ER 
and oxycodone ER provided excellent and comparable 
analgesia with low requirements for rescue analgesics. The 
equianalgesic ratio of oxycodone ER to oxymorphone ER 
was found to be 2:1.Therapeutics and Clinical Risk Management 2008:4(4) 783
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Six clinical trials have been published demonstrating 
the effectiveness of oxymorphone ER for the treatment of 
CNMP. The largest published clinical trial (Matsumoto 
et al 2005) found oxymorphone ER to be effective in the 
treatment of moderate-to-severe pain from osteoarthritis. 
Patients (n = 269) with osteoarthritis of the knee or hip 
completed the 1 month double-blind clinical trial comparing 
two doses of oxymorphone ER (20 and 40 mg q12 h) with 
oxycodone ER (20 mg q12 h) or placebo. Both doses of oxy-
morphone ER provided superior pain relief and improved 
physical functioning compared with the placebo group, 
with typical opioid side effects reported for both opioid 
medications. The longest prospective trial of oxymorphone 
ER (McIlwain and Ahdieh 2005) was completed in patients 
with pain from osteoarthritis who were followed over a 
1-year period. This open-label extension study followed 
153 patients (with 61 patients completing the 1-year trial) 
and achieving pain relief with titration of oxymorphone 
20 or 40 mg twice daily. No rescue opioid analgesics were 
used during the study. Pain relief was excellent (Figure 6) 
with a mean current VAS pain intensity score at end-of-study 
of 20 mm, an approximate 60% reduction in pain rating 
compared with initiation of the trial. The mean daily dose of 
oxymorphone ER at end-of-study was 62 mg, and remained 
very stable throughout the 1-year trial. Typical opioid side 
effects were reported and were the most common reason 
for withdrawal from study. No serious adverse events were 
noted. Interestingly, no instances of opioid addiction or drug 
misuse were recorded.
Two very recent studies have reported the use of oxy-
morphone ER for the relief of chronic low back pain (CLBP) 
over a 3-month clinical trial. Katz and colleagues (Katz et al 
2007) titrated 325 opioid-naïve patients with CLBP using 
oxymorphone ER given twice daily, and then randomized 
patients to either continue the oxymorphone ER or receive 
placebo. Oxymorphone IR was always available for rescue 
analgesia. Two hundred and ﬁ  ve patients were stabilized on 
oxymorphone ER with a mean VAS pain intensity rating 
decrease from 69 at screening to 23 at completion of titra-
tion. After randomization, and as expected, pain intensity 
increased signiﬁ  cantly more in the placebo group, in spite 
of available oxymorphone IR rescue opioid, compared with 
the opioid treatment group. The authors concluded that 
stabilized doses of oxymorphone ER were generally safe 
and effective over a 12-week double-blind treatment period 
in opioid-naïve patients with CLBP (Katz et al 2007). This 
study is important because patients with CLBP represent the 
largest group of patient visits to most chronic pain clinics. A 
similar clinical trial (Hale et al 2007) converted 143 patients 
with CLBP from their chronic opioid to oxymorphone ER, 
and then randomized the patients to either continue the 
oxymorphone ER or receive placebo. Pain intensity was 
better in the oxymorphone ER group compared with the 
placebo (with oxymorphone IR rescue analgesics) group, 
Figure 4 Mean (SEM) visual analog scale daily pain scores (0 = no pain, 10 = worst pain) for all cancer patients receiving MS Contin® (morphine sulfate), OxyContin® (oxycodone 
continuous release), and oxymorphone ER.
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and opioid-related side effects were mild and similar between 
groups. For opioid-experienced patients with CLBP, oxymor-
phone ER provided long-term analgesia that was generally 
well tolerated (Hale et al 2007).
Adverse effects
Typical opioid side effects (nausea, vomiting, constipa-
tion, sedation, dry mouth) have been reported with all 
the published clinical trials to date, usually mild, with no 
serious adverse events yet reported. As with all opioids for 
chronic pain management, some patients will discontinue 
analgesics because of intolerable side effects. In published 
studies of oxymorphone to date, the highest rate of medica-
tion withdrawal secondary to side effects occurred among 
opioid-naïve patients started on a relatively high dose of 
oxymorphone ER (20 mg twice daily) with no titration 
period (McIlwain and Ahdieh 2005). It is likely that the rate 
of acceptance of oxymorphone as analgesic can be improved 
using a lower opioid dose (Gimbel et al 2005) with slow 
upward titration as is recommended for all opioids (Sloan 
and Babul 2006). Although no evidence of opioid misuse 
has been reported in available clinical trials, it is likely that 
oxymorphone ER has an opioid addiction potential similar 
to current available opioids.
Respiratory depression may occur with higher doses 
(The Medical Letter 2007), as with all opioids. Chronic 
oxymorphone use will result in physical dependence, 
which means that the drug should be tapered slowly rather 
than abrupt discontinuation. Physical dependence does not 
imply psychological addiction. Opioids have recently been 
implicated to interfere with the immune system (Sacerdote 
2006). The interaction of oxymorphone with the immune 
system has not been investigated. Oxymorphone adminis-
tered in large doses to rodents has not been found to be car-
cinogenic (Shuey et al 2007). Recent research has suggested 
that chronic opioids may reduce androgen levels in men by 
suppressing the hypothalamic-pituitary-gonadal axis (Daniel 
et al 2006). It is likely that oxymorphone may produce the 
same side effect of reduction in testosterone levels.
Dosing guidelines
Oxymorphone IR may be used as needed in the treatment 
of acute postsurgical pain with a dose of 5–10 mg every 
4 hours. The IR formulation will also be used as a 
breakthrough medication for patients on chronic oxymor-
phone ER for chronic pain management, given as a dose of 
10% of the total daily oxymorphone ER dose every 2 hours 
as needed. Finally, for opioid-naïve patients, oxymorphone 
IR (5–10 mg q4–6 h) is often used to titrate patients to 
acceptable pain relief with slow upward dose titration and 
then convert patients to the ER formulation after arriving at 
a stable daily dose. Oxymorphone should be administered 
on an empty stomach. As with any opioid, it is vital to adjust 
the dosing regimen for each patient individually, taking 
into account the patient’s prior analgesic therapy (Endo 
Pharmaceuticals 2007).
Figure 5 Mean (SEM) opioid daily dose for all cancer patients receiving MS Contin® (morphine sulfate), OxyContin® (oxycodone continuous release), and oxymorphone ER.
Treatment Days
MS Contin to Oxymorphone ER Oxycontin to Oxymorphone ER
OxyContin Treatment
Oxymorphone ER Treatment
MS Contin Treatment
350
300
250
200
150
100
50
0
−7 −6 −5 −4 −3 −2 −1 1234567
T
o
t
a
l
 
O
p
i
o
i
d
 
D
a
i
l
y
 
D
o
s
e
 
(
m
g
)
(
M
e
a
n
 
+
/
-
 
S
E
M
)Therapeutics and Clinical Risk Management 2008:4(4) 785
Oxymorphone for pain management
Because of individual patient variability in response to 
opioid analgesics, opioid rotation is becoming more com-
mon to achieve improved balance between opioid analgesic 
effect and adverse effects (Mercadante and Bruera 2006; 
Freye et al 2007). For opioid conversion to oxymorphone 
ER, oxycodone ER and morphine ER may be calculated 
to be equipotent and half as potent as oxymorphone ER, 
respectively (Sloan et al 2005). Because other opioids have 
not been directly compared with oxymorphone, published 
dose conversion tables may be used to convert other opioids 
ﬁ  rst to morphine daily equivalents, and then complete the 
estimated conversion to oxymorphone. The clinician must 
always start the oxymorphone ER using approximately 
half of the calculated dose, since incomplete opioid cross 
tolerance exists. Once therapy has been initiated, pain relief 
and side effects should be closely monitored with dosage 
adjustment accordingly.
Oxymorphone ER should be prescribed every 12 hours. 
While other ER opioid formulations also recommend 
12 hourly dosing, recent studies suggest that patients often use 
the medication on an 8-hourly schedule (Sinatra 2006). Because 
plasma levels of oxymorphone ER and analgesia are clearly 
sustained over 12 hours (Ahdieh et al 2004), it may truly be 
utilized as a 12-hour opioid formulation. Additional long-term 
studies are needed to determine if this is a legitimate advantage 
of oxymorphone ER over other opioid ER products.
The occasional cancer patient may use parenteral oxy-
morphone on a chronic daily basis. Given the low oral 
bioavailability of oxymorphone, parenteral oxymorphone 
may be converted to oral oxymorphone by a factor of 10.
Precautions
Oxymorphone should be used cautiously (start with a low 
dose and titrate upward very slowly) in patients with hepatic 
disease as the plasma concentrations achieved are greater than 
in patients with normal liver function (Endo Pharmaceuticals 
2007). The package insert advises that oxymorphone is 
contraindicated in patients with moderate or severe liver 
dysfunction (Endo Pharmaceuticals 2007). Oxymorphone 
bioavailability is reported to increase 57%–65% in patients 
with moderate to severe renal impairment (Endo Pharma-
ceuticals 2007), thus is should be administered cautiously 
and in reduced dosages. Oxymorphone has been found to be 
removed by hemodialysis (Lee et al 2005), yet the clinician 
would be wise to dose cautiously even for the patient on 
dialysis, since opioid accumulation may still occur (Foral 
et al 2007).
Oxymorphone should be used cautiously when combined 
with other CNS depressants, and in patients with severe 
pulmonary impairment. Oxymorphone should not be used in 
combination with alcohol products. Oxymorphone metabo-
lism occurs in the liver, but does not signiﬁ  cantly involve the 
cytochrome P450 enzyme system (Adams et al 2005), thus it 
differs from other opioids (such as oxycodone, methadone) 
and may reduce the potential for drug – drug interactions 
(Kivitz et al 2006).
Conclusions
The treatment of chronic cancer and nonmalignant pain 
requires the use of chronic opioids for many patients. While 
there are several opioids currently are on the market, new 
Figure 6 Mean current visual analog scale pain intensity (0 = no pain; 100 = worst pain) over a one-year clinical trial of oxymorphone ER for arthritis pain. (The number of 
patients included in scoring is given above the error bar for each assessment) Reprinted with permission from McIlwain H, Ahdieh H. 2005. Safety, tolerability, and effectiveness 
of oxymorphone extended-release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther, 12:106–12. Copyright © Lippincott Williams and Wilkins.
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Sloan
formulations are welcomed because the variable patient 
response to a particular opioid product results in many patients 
rotating to several different opioids before adequate balance 
of analgesia and side effect is achieved. Oral oxymorphone, 
in both IR and ER formulations, has become available for the 
treatment of acute and chronic signiﬁ  cant pain. Clinical trials 
of oxymorphone demonstrate efﬁ  cacy and safety, with typical 
opioid side effects, for the management of postsurgical pain, 
chronic arthritis pain, chronic low back pain, and chronic can-
cer pain. Oxymorphone has an advantage over some opioids 
in that it is now available in both parenteral and oral (IR and 
ER) formulations which leads to easy titration and conversion 
when patients experience formulation changes. Oxymorphone 
ER has been shown to be efﬁ  cacious over the 12-hour dosing 
interval in clinical trials varying from 2 to 52 weeks. With 
proper dose titration, oral oxymorphone is an effective opioid 
that provides a new therapeutic option for the clinician. Future 
studies should continue to document the clinical efﬁ  cacy of 
oral oxymorphone in long-term clinical trials (greater than 
6 months) of cancer and CNMP, and should investigate the 
dose conversion from oxymorphone to other common opioids 
in use (eg, methadone, fentanyl patch).
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